Elasmogen is using a combination of in-house development and strategic partnerships to accelerate an expanding pipeline of new and differentiated drug products towards clinical studies.
In-house
Auto-immune mediated anti-inflammatory programmes ELN/21 and ELN/22
Strategic Partnerships
soloMER Drug Conjugate (SDC) programme with Almac Discovery Ltd (ELN/ 11) and a Bio-processing programme with Merck Inc (ELN/ 10).